Global Pharmaceutical Mass Flow Controller Market - 2020-2027
発行: DataM Intelligence
ページ情報: 英文 183 Pages
The global pharmaceutical mass flow controller market is expected to grow at a CAGR of 6.4% during the forecasting period (2020-2027), owing to growing demand for low flow rate controlling devices for precise measurements. Increasing developments in the laboratory & biomedical research sector that requires gas flow measurement under controlled conditions is expected to drive the mass flow controller market growth over the forecast period.
The global pharmaceutical mass flow controller market is multiplying due to the rising need for reliable and efficient measurement of liquid and gas flow. There are many challenges faced by the pharmaceutical industry during productions of various products. Hence, precise measurements are required to control and accuracy throughout the production processes.
By using mass flow controllers, pharmaceutical companies have improved the accuracy and reliability of air flow measurement; improved performance of the air handling units; and reduced installation and maintenance costs. As medical & Pharmaceutical market is growing due to growing aging population, the mass flow controller for the pharmaceutical industry is expected grow with more opportunities.
Current and Post-COVID-19 growth prospects in pharmaceuticals and healthcare industries are the major factors driving the growth of the pharmaceuticals mass flow controller market. Mass flow controllers play an crucial role in the quality control of different types of medical devices, and several major companies have grabbed the opportunity to fight against the deadly coronavirus pandemic. For instance, RedySmart mass flow controllers of Sierra Instruments provide critical gas flow control systems for bioreactors to scale vaccines from lab to pilot to full-scale production.
The mass flow controller (MFC) is commonly used in many bioprocessing systems to manage the flow of different gases into bioreactor chambers. Intelligent MFC technology with digital-based flow-control capabilities can help deliver more precise and versatile gas flow control, more sophisticated analysis, and resolution of process issues, and can also help equip bioprocess scientists and engineers with data that could lead to improved bioreactor performance. It plays an essential role in maintaining a bioreactor's-controlled environment and achieving optimal cell growth.
Two critical factors that govern cell culture yield are the levels of dissolved oxygen (DO) in the bioreactor and the pH of the fermentation broth. For bioprocessing engineers, who focus on optimizing performance, controlling costs, and satisfying strict regulatory requirements MFCs provide a key tool for managing specific bioreactors as well as overall bioprocessing system performance, reducing unscheduled downtime and maximizing integrity tester and bioreactor uptime and yields. The mass flow controller (MFC) has the application of bioreactors, including fermenters, are for production of bioethanol and other biofuels, pharmaceutical products, fine chemical products, food and beverages and tissue growth. As dosing of Air, N2, O2 and CO2 into microbial and cell cultivation is critical.
Based on product type pharmaceutical mass flow controller market is segmented by Thermal Flow Meter, Differential Pressure Flow Meter, Coriolis Mass Flow Meter and others. As the temperature probes need only a very small cross-section, their impact on gas flow is minimal. Thus, one of the biggest advantages of the thermal mass flow meter is that it imposes negligible pressure drop. As the pharmaceutical industry uses a lot gas, thermal mass flow meters are the preferred over other meters for gas flow measurement. Thermal mass flow meters has several advantages such as:
The North America is expected to hold the largest share of about XX% in the global pharmaceutical mass flow controller market in 2019, owing to the increasing implementation of these controllers in pharmaceutical industries.
North America pharmaceutical mass flow controller and it is estimated to grow at a CAGR of 6.5% during the forecast period (2020-2027) As of 2019, there are more than 800 active Investigational New Drug (IND) waiting for approval with the FDA. These burgeoning approvals and drug-developing pipelines are expected to promise more opportunities to market. Apart from this, the US Government has increased the overall healthcare expenditure propelling the market growth. Pharmaceutical manufacturers have increased the investments in R&D for the development of better-quality mass flow controller since it has a direct effect on the safety and efficacy of the drug.
For instance, ventilation devices used during emergency treatment are required for providing an optimum flow of oxygen to the ailing patient. In this case, the performance capability of mass flow controllers is crucial.
The United States healthcare spending is expected to have a 0.8% faster growth than the gross domestic product (GDP) per year over the 2018-27 period. The health share of GDP would rise from 17.9% in 2017 to 19.4% by 2027, as per estimates from the Centers for Medicare & Medicaid Services. The stricter regulation in the country ensures superior quality of the manufacturing and the end-product that is being adhered to by the CMOs.
The pharmaceutical mass flow controller is a fragmented market with the presence of large number of market players. The key players operating in pharmaceuticals mass flow controller market include Azbil Corporation, Brooks Instrument, Bronkhorst, Burkert, Sierra Instrument, Vogtlin, Tokyo Keiso, Teledyne Hastings, Alicat Scientific, and Parker Hannifin.
These companies are launching new innovative solutions with advanced technologies. They are focused on providing efficient products to consumer industries to gain a competitive edge.
The key market players are adopting various strategies such as mergers and acquisitions, product approvals, and agreements to increase product reach and strengthen their product portfolios, in order to enter or expand their business offerings and competitiveness in the pharmaceutical mass flow controller market. For instance, In December 2020, Brooks Instrument, added the GT1600 Series of glass tube variable area flow meters to its industry-leading family of variable area flow meter products. Suitable for a wide variety of industries from chemical manufacturing to pharmaceutical production to water treatment and distribution, the GT1600 is ideal for low- and high-flow gas and liquid applications where viewing the process is important. In October 2019, MKS Instruments launched next-generation C-series mass flow controllers, which uses Micro-Electromechanical Systems (MEMS) technology combined with a fast-acting control valve and MKS proprietary algorithms resulting in an ultra-fast control time of less than 100 milliseconds.
In July 2019, Brooks Instrument (US) launched two new mass flow controllers- the SLA5800 Series Biotech and the SLAMf series Biotech designed for biotechnology applications. In January 2019, Bronkhorst High-Tech (Netherlands) launched the IN-FLOW series of mass flow meters and controllers featuring a rugged, IP65-rated dustproof and waterproof design. Available for flow ranges from 0.05-1 mln/min up to 200-10000 m³n/h air-equivalent, the IN-FLOW series flow meters come with optional ATEX approval for use in Category 3, Zone 2 hazardous areas and are now offered with FM approval for Class I, Division 2 to meet the needs of the North American market.